706 related articles for article (PubMed ID: 30006154)
21. Overexpression of NAG-1/GDF15 prevents hepatic steatosis through inhibiting oxidative stress-mediated dsDNA release and AIM2 inflammasome activation.
Wang Y; Chen C; Chen J; Sang T; Peng H; Lin X; Zhao Q; Chen S; Eling T; Wang X
Redox Biol; 2022 Jun; 52():102322. PubMed ID: 35504134
[TBL] [Abstract][Full Text] [Related]
22. Integrated omics analysis for characterization of the contribution of high fructose corn syrup to non-alcoholic fatty liver disease in obesity.
Papadopoulos G; Legaki AI; Georgila K; Vorkas P; Giannousi E; Stamatakis G; Moustakas II; Petrocheilou M; Pyrina I; Gercken B; Kassi E; Chavakis T; Pateras IS; Panayotou G; Gika H; Samiotaki M; Eliopoulos AG; Chatzigeorgiou A
Metabolism; 2023 Jul; 144():155552. PubMed ID: 36996933
[TBL] [Abstract][Full Text] [Related]
23. Resveratrol prevents hepatic steatosis and endoplasmic reticulum stress and regulates the expression of genes involved in lipid metabolism, insulin resistance, and inflammation in rats.
Pan QR; Ren YL; Liu WX; Hu YJ; Zheng JS; Xu Y; Wang G
Nutr Res; 2015 Jul; 35(7):576-84. PubMed ID: 26055348
[TBL] [Abstract][Full Text] [Related]
24. Attenuation of hepatic steatosis by purple sweet potato colour is associated with blocking Src/ERK/C/EBPβ signalling in high-fat-diet-treated mice.
Wang X; Zhang ZF; Zheng GH; Wang AM; Sun CH; Qin SP; Zhuang J; Lu J; Ma DF; Zheng YL
Appl Physiol Nutr Metab; 2017 Oct; 42(10):1082-1091. PubMed ID: 28636830
[TBL] [Abstract][Full Text] [Related]
25. Biochanin A improves hepatic steatosis and insulin resistance by regulating the hepatic lipid and glucose metabolic pathways in diet-induced obese mice.
Park HS; Hur HJ; Kim SH; Park SJ; Hong MJ; Sung MJ; Kwon DY; Kim MS
Mol Nutr Food Res; 2016 Sep; 60(9):1944-55. PubMed ID: 27145114
[TBL] [Abstract][Full Text] [Related]
26.
Park M; Yoo JH; Lee YS; Lee HJ
Nutrients; 2019 Feb; 11(3):. PubMed ID: 30813654
[TBL] [Abstract][Full Text] [Related]
27. Nimesulide, a cyclooxygenase-2 selective inhibitor, suppresses obesity-related non-alcoholic fatty liver disease and hepatic insulin resistance through the regulation of peroxisome proliferator-activated receptor γ.
Tsujimoto S; Kishina M; Koda M; Yamamoto Y; Tanaka K; Harada Y; Yoshida A; Hisatome I
Int J Mol Med; 2016 Sep; 38(3):721-8. PubMed ID: 27431935
[TBL] [Abstract][Full Text] [Related]
28. Sake lees extract improves hepatic lipid accumulation in high fat diet-fed mice.
Kubo H; Hoshi M; Matsumoto T; Irie M; Oura S; Tsutsumi H; Hata Y; Yamamoto Y; Saito K
Lipids Health Dis; 2017 Jun; 16(1):106. PubMed ID: 28578672
[TBL] [Abstract][Full Text] [Related]
29. Niacin Ameliorates Hepatic Steatosis by Inhibiting De Novo Lipogenesis Via a GPR109A-Mediated PKC-ERK1/2-AMPK Signaling Pathway in C57BL/6 Mice Fed a High-Fat Diet.
Ye L; Cao Z; Lai X; Shi Y; Zhou N
J Nutr; 2020 Apr; 150(4):672-684. PubMed ID: 31858105
[TBL] [Abstract][Full Text] [Related]
30. REDD1 deficiency protects against nonalcoholic hepatic steatosis induced by high-fat diet.
Dumas K; Ayachi C; Gilleron J; Lacas-Gervais S; Pastor F; Favier FB; Peraldi P; Vaillant N; Yvan-Charvet L; Bonnafous S; Patouraux S; Anty R; Tran A; Gual P; Cormont M; Tanti JF; Giorgetti-Peraldi S
FASEB J; 2020 Apr; 34(4):5046-5060. PubMed ID: 32043636
[TBL] [Abstract][Full Text] [Related]
31. Thrombospondin 1 improves hepatic steatosis in diet-induced insulin-resistant mice and is associated with hepatic fat content in humans.
Bai J; Xia M; Xue Y; Ma F; Cui A; Sun Y; Han Y; Xu X; Zhang F; Hu Z; Liu Z; Liu Y; Cai G; Su W; Sun X; Wu H; Yan H; Chang X; Hu X; Bian H; Xia P; Gao J; Li Y; Gao X
EBioMedicine; 2020 Jul; 57():102849. PubMed ID: 32580141
[TBL] [Abstract][Full Text] [Related]
32. iPLA2β deficiency attenuates obesity and hepatic steatosis in ob/ob mice through hepatic fatty-acyl phospholipid remodeling.
Deng X; Wang J; Jiao L; Utaipan T; Tuma-Kellner S; Schmitz G; Liebisch G; Stremmel W; Chamulitrat W
Biochim Biophys Acta; 2016 May; 1861(5):449-61. PubMed ID: 26873633
[TBL] [Abstract][Full Text] [Related]
33. Mindin/Spondin 2 inhibits hepatic steatosis, insulin resistance, and obesity via interaction with peroxisome proliferator-activated receptor α in mice.
Zhu LH; Wang A; Luo P; Wang X; Jiang DS; Deng W; Zhang X; Wang T; Liu Y; Gao L; Zhang S; Zhang X; Zhang J; Li H
J Hepatol; 2014 May; 60(5):1046-54. PubMed ID: 24445216
[TBL] [Abstract][Full Text] [Related]
34. Pioglitazone attenuates hepatic inflammation and fibrosis in phosphatidylethanolamine N-methyltransferase-deficient mice.
van der Veen JN; Lingrell S; Gao X; Quiroga AD; Takawale A; Armstrong EA; Yager JY; Kassiri Z; Lehner R; Vance DE; Jacobs RL
Am J Physiol Gastrointest Liver Physiol; 2016 Apr; 310(7):G526-38. PubMed ID: 26797396
[TBL] [Abstract][Full Text] [Related]
35. Lack of ClC-2 Alleviates High Fat Diet-Induced Insulin Resistance and Non-Alcoholic Fatty Liver Disease.
Fu D; Cui H; Zhang Y
Cell Physiol Biochem; 2018; 45(6):2187-2198. PubMed ID: 29550812
[TBL] [Abstract][Full Text] [Related]
36. Hepatocyte-specific Ptpn6 deletion promotes hepatic lipid accretion, but reduces NAFLD in diet-induced obesity: potential role of PPARγ.
Xu E; Forest MP; Schwab M; Avramoglu RK; St-Amand E; Caron AZ; Bellmann K; Shum M; Voisin G; Paquet M; Montoudis A; Lévy E; Siminovitch KA; Neel BG; Beauchemin N; Marette A
Hepatology; 2014 May; 59(5):1803-15. PubMed ID: 24327268
[TBL] [Abstract][Full Text] [Related]
37. Peroxisome proliferator-activated receptor-delta agonist ameliorated inflammasome activation in nonalcoholic fatty liver disease.
Lee HJ; Yeon JE; Ko EJ; Yoon EL; Suh SJ; Kang K; Kim HR; Kang SH; Yoo YJ; Je J; Lee BJ; Kim JH; Seo YS; Yim HJ; Byun KS
World J Gastroenterol; 2015 Dec; 21(45):12787-99. PubMed ID: 26668503
[TBL] [Abstract][Full Text] [Related]
38. Voluntary exercise in mice fed an obesogenic diet alters the hepatic immune phenotype and improves metabolic parameters - an animal model of life style intervention in NAFLD.
Gehrke N; Biedenbach J; Huber Y; Straub BK; Galle PR; Simon P; Schattenberg JM
Sci Rep; 2019 Mar; 9(1):4007. PubMed ID: 30850619
[TBL] [Abstract][Full Text] [Related]
39. Caffeine affects HFD-induced hepatic steatosis by multifactorial intervention.
Helal MG; Ayoub SE; Elkashefand WF; Ibrahim TM
Hum Exp Toxicol; 2018 Sep; 37(9):983-990. PubMed ID: 29249184
[TBL] [Abstract][Full Text] [Related]
40. IGFBP5 modulates lipid metabolism and insulin sensitivity through activating AMPK pathway in non-alcoholic fatty liver disease.
Xiao Z; Chu Y; Qin W
Life Sci; 2020 Sep; 256():117997. PubMed ID: 32585242
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
